A new hope in the battle against respiratory virus infections!

A new hope in the battle against respiratory virus infections!

Poolbeg Pharma licences first-in-class broad spectrum RNA-based immunotherapy for respiratory virus infections from the University of Warwick.

Administered intra-nasally, this RNA-based immunotherapy works by triggering nasal cells into an antiviral state to protect from the infecting virus. Simultaneously, it blocks the cells from making more virus by directly preventing its replication. Both modes of action combined can reduce infectious viral loads and improve disease symptoms. This could potentially provide an effective solution for protecting at risk patient populations (e.g. the elderly, COPD patients, and asthmatics).

Read more here:- https://warwickinnovationdistrict.com/2022/01/17/poolbeg-pharma-licences-first-in-class-broad-spectrum-rna-based-immunotherapy-for-respiratory-virus-infections-from-the-university-of-warwick/